ATE439137T1 - Behandlung von hämatologischen störungen - Google Patents

Behandlung von hämatologischen störungen

Info

Publication number
ATE439137T1
ATE439137T1 AT98960199T AT98960199T ATE439137T1 AT E439137 T1 ATE439137 T1 AT E439137T1 AT 98960199 T AT98960199 T AT 98960199T AT 98960199 T AT98960199 T AT 98960199T AT E439137 T1 ATE439137 T1 AT E439137T1
Authority
AT
Austria
Prior art keywords
treatment
hematological disorders
neoplastic
gvhd
hematologic
Prior art date
Application number
AT98960199T
Other languages
English (en)
Inventor
Megan Sykes
Thomas Spitzer
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE439137T1 publication Critical patent/ATE439137T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cereal-Derived Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98960199T 1997-11-14 1998-11-13 Behandlung von hämatologischen störungen ATE439137T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7323097P 1997-11-14 1997-11-14
PCT/US1998/024209 WO1999025367A2 (en) 1997-11-14 1998-11-13 Treatment of hematologic disorders

Publications (1)

Publication Number Publication Date
ATE439137T1 true ATE439137T1 (de) 2009-08-15

Family

ID=22112521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960199T ATE439137T1 (de) 1997-11-14 1998-11-13 Behandlung von hämatologischen störungen

Country Status (8)

Country Link
US (3) US6558662B2 (de)
EP (1) EP1030675B1 (de)
JP (1) JP2001523645A (de)
AT (1) ATE439137T1 (de)
AU (1) AU1585799A (de)
CA (1) CA2309919A1 (de)
DE (1) DE69841058D1 (de)
WO (1) WO1999025367A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309919A1 (en) * 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
DE10050334A1 (de) * 2000-10-11 2002-04-25 Gsf Forschungszentrum Umwelt Verwendung von Stammzellen und CD6-depletierten Stammzellen zur Toleranzinduktion gegenüber allogenen Transplantaten und/oder zur Leukämiebehandlung
AU2002219828A1 (en) * 2000-11-14 2002-05-27 The General Hospital Corporation Blockade of T cell migration into epithelial GVHD target tissues
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
AU2002309703A1 (en) * 2001-05-09 2002-11-18 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
US20030147859A1 (en) * 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
US20030032631A1 (en) * 2001-08-13 2003-02-13 Mcdonald George B. Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
US20040005315A1 (en) * 2002-05-22 2004-01-08 Siemionow Maria Z. Induction and maintenance of tolerance to composite tissue allografts
US20040071666A1 (en) * 2002-05-24 2004-04-15 The Regents Of The University Of Michigan Compositions and methods related to graft-versus-host disease
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
JP2006517975A (ja) * 2003-02-13 2006-08-03 アンスロジェネシス コーポレーション 疾患、障害または症状を患っている個体を治療するための臍帯血の使用
JP2004256444A (ja) * 2003-02-26 2004-09-16 Kansai Tlo Kk 悪性腫瘍の治療方法
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
WO2005030999A1 (en) * 2003-09-25 2005-04-07 Dana-Farber Cancer Institute, Inc Methods to detect lineage-specific cells
EP1689435A4 (de) * 2003-10-22 2007-10-03 Univ Rochester Anti-thymozyten-antiserum und seine verwendung zur auslösung von b-zell-apoptose
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
JP2007087270A (ja) * 2005-09-26 2007-04-05 Tsukuba Brains Kk 再生医療支援システム
EP2345412A1 (de) * 2005-12-02 2011-07-20 The Johns Hopkins University Verwendung von hochdosierten Oxazaphosphorinmedikamenten zur Behandlung von Immunstörungen
US20070179810A1 (en) * 2006-01-05 2007-08-02 Goodman Edward L Controls for antimicrobial use and infection
US8383095B2 (en) * 2006-02-14 2013-02-26 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008128299A1 (en) * 2007-04-24 2008-10-30 Murdoch Childrens Research Institute Therapeutic protocol for treating hemoglobinopathy
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs
EP2225563B1 (de) * 2007-11-27 2015-01-21 Janssen Diagnostics, LLC Automatische zählung und charakterisierung von im blut zirkulierenden melanomzellen
JP2011529078A (ja) * 2008-07-25 2011-12-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 自己免疫疾患を治療および予防するための方法および組成物
US9682106B2 (en) 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
RU2728867C2 (ru) * 2011-04-20 2020-07-31 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл
CA2859952C (en) * 2011-12-22 2023-04-04 Yeda Research And Development Co. Ltd. A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion
EP2838568A4 (de) * 2012-04-20 2015-12-09 Angimmune Llc Immunmodulation durch anti-cd3-immuntoxine zur behandlung von karzinomen ohne einheitliches oberflächen-cd3
CA2902098A1 (en) 2013-02-26 2014-09-04 The Board Of Trustees Of The Leland Stanford Junior University Combined organ and hematopoietic cells for transplantation tolerance of grafts
EP3932414A1 (de) * 2015-11-10 2022-01-05 City of Hope Konditionierungsschemen und verfahren zur induzierung von gemischtem chimärismus
US10426798B2 (en) 2017-07-18 2019-10-01 Calimmune, Inc. Modulatable switch for selection of donor modified cells
EA202090922A1 (ru) * 2017-11-29 2021-03-09 Маджента Терапьютикс, Инк. Композиции и способы истощения cd2+ клеток
WO2019178106A1 (en) 2018-03-12 2019-09-19 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
AU2019374064A1 (en) * 2018-10-31 2021-05-20 Magenta Therapeutics Inc. Methods for hematopoietic stem and progenitor cell transplant therapy
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3965782A4 (de) * 2019-05-09 2023-03-08 The General Hospital Corporation Verfahren zur induktion von hämatopoetischem chimärismus
EP4142755A4 (de) * 2020-04-27 2024-06-12 Children's Hospital Medical Center Präzisionsdosierschema
WO2022040210A1 (en) * 2020-08-18 2022-02-24 City Of Hope Haploidentical mixed chimerism for treating autoimmune diseases
EP4247940A1 (de) * 2020-11-18 2023-09-27 The Regents of the University of California Entfernung monoklonaler antikörper gegen natürliche killerzellen

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
JPH07503012A (ja) 1992-01-08 1995-03-30 ザ ジェネラル ホスピタル コーポレイション 異種移植のための誘導された寛容
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
EP0687300B1 (de) 1993-03-05 2001-09-12 Universite Catholique De Louvain Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
AU7404494A (en) * 1993-07-21 1995-02-20 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
CA2186527A1 (en) * 1994-03-31 1995-10-12 Thomas Fraser Improved methods for transplantation using modified cells and t cell inhibitory agents
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
DE69723888T2 (de) * 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
JP2002514193A (ja) 1996-11-15 2002-05-14 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植のためのコンディショニング
CA2309919A1 (en) * 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders

Also Published As

Publication number Publication date
US7892578B2 (en) 2011-02-22
DE69841058D1 (de) 2009-09-24
WO1999025367A3 (en) 1999-08-05
JP2001523645A (ja) 2001-11-27
US6558662B2 (en) 2003-05-06
US20030157077A1 (en) 2003-08-21
AU1585799A (en) 1999-06-07
US20010048921A1 (en) 2001-12-06
US7408039B2 (en) 2008-08-05
EP1030675A2 (de) 2000-08-30
US20090028870A1 (en) 2009-01-29
CA2309919A1 (en) 1999-05-27
EP1030675B1 (de) 2009-08-12
WO1999025367A2 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
ATE439137T1 (de) Behandlung von hämatologischen störungen
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
PL328858A1 (en) Immunogenous peptides
IL189629A0 (en) Compositions containing human ctla-4 antibodies
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE3483040D1 (de) Maschinelesbares dokument und dessen behandlung.
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69316948D1 (de) Lösliche Liganden für CD40
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
ATE220557T1 (de) Darmprotozoen-impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties